In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orexigen Offers Robust Contrave Risk Plan To Monitor For Safety Concerns

Executive Summary

Orexigen brought a robust risk management plan and a post-market surveillance program to the Dec. 7 advisory committee review of its weight-loss drug Contrave, forestalling some of the questions that arose during assessments of other compounds seeking to enter the obesity space.
Advertisement

Related Content

Positive Panel Recommendation For Contrave Could Change Obesity Drug Game
Panel Continues To Push For Obesity CV Guidance As It Backs Contrave Approval
Panel Continues To Push For Obesity CV Guidance As It Backs Contrave Approval
Positive Panel Recommendation For Contrave Could Change Obesity Drug Game
Panel Continues To Push For Obesity CV Guidance As It Backs Contrave Approval
REMS For Obesity Drugs May Need More Specifics After Qnexa Advisory Panel
REMS For Obesity Drugs May Need More Specifics After Qnexa Advisory Panel
Qnexa May Get Staged Launch After No Vote From Advisory Panel

Topics

Advertisement
UsernamePublicRestriction

Register

PS052934

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel